StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

Equities research analysts at StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Trading Down 15.7 %

Shares of PIRS stock opened at $13.60 on Friday. The firm’s 50 day moving average is $15.39 and its 200 day moving average is $14.98. The stock has a market capitalization of $17.95 million, a P/E ratio of -1.12 and a beta of 0.61. Pieris Pharmaceuticals has a 12 month low of $6.20 and a 12 month high of $22.32.

Institutional Trading of Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC purchased a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for 0.4% of BML Capital Management LLC’s holdings, making the stock its 21st largest position. BML Capital Management LLC owned 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.